3 hrs ago | Inside Bay Area
On May 14, The New York Times published a moving essay by Angelina Jolie in which the actor revealed she had undergone a double mastectomy -- even though she did not have breast cancer.
7 hrs ago | Southwest Riverside News Network
A private company will begin assessing the hazardous conditions near La Jolla Cove caused by accumulated bird guano and its overwhelming stench this weekend, and planned to apply a product to neutralize the stench in a portion of the affected area on Tuesday, it was announced.
11 hrs ago | WTOP-FM Washington
Intercounty Connector -- peak service routes 202, 203, and 204, which serve Gaithersburg, the Shady Grove Metro Station and Walter-Reed-Bethesda. The MTA claims the lines have low ridership.
16 hrs ago | KFOXTV
Georgia stands to lose $1.8 million in health-related funding because state officials refuse to participate in a federal survey that asks students from seventh grade through high school questions about their sexual histories.
20 hrs ago | Fortune
My client knew the lawsuit was coming. The employee had threatened to sue her employer just about every day.
San Diego officials have announced a plan to rid the scenic beaches of La Jolla of bird poop smell after declaring the excrement a health hazard.
ISTA Pharmaceuticals Inc. pleaded guilty on Friday in a federal case involving its eye drug Xibrom, admitting it promoted the drug for unapproved uses and agreeing to pay $33.5 million in fines and fees.
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Stefan Oschmann came courting biotechnology start-ups last week, a trans-Atlantic visitor promising not only pharmaceutical industry expertise but also cash.
Danish drug maker Novo Nordisk said it could launch obesity treatment liraglutide in the United States by the end of next year and rejected some analysts' doubts over the medicine's commercial potential.
Forest Laboratories Inc said Howard Solomon, its chief executive of more than 35 years, will retire at the end of this year, capping a tenure that saw the company morph from a small generic and vitamins maker to a $10 billion corporation.
Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during a review of the health care giant's medicine business.
BIG PLANS: Johnson & Johnson says it's poised by 2017 to seek regulatory approval for a dozen new medicines and two dozen variations of existing ones.
Drowning was the most common cause of death associated with the Oct. 29 Superstorm Sandy, according to a new report out Thursday from Centers for Disease Control and Prevention.
A federal panel of medical experts said that an experimental insomnia drug from Merck & Co.
Johnson & Johnson says it plans to submit more than 10 new treatments to regulators for approval and 25 applications for additional uses of approved drugs by 2017.
A report by the Centers for Disease Control and Prevention is showing a big drop in teen birth rates that some experts say is startling.